Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

NT-proBNP by itself predicts mortality and CV outcomes in T2DM

Literature - Oct. 20, 2020 - Malachias MVB, et al. - J Am Heart Assoc. 2020

The biomarker NT-proBNP was as predictive as a traditional multivariable risk model for both death and CV events in T2DM patients with CVD and/or CKD.

FDA Breakthrough Therapy Designation for SGLT2i in chronic kidney disease

News - Oct. 13, 2020

The SGLT2 inhibitor dapagliflozin has been granted Breakthrough Therapy Designation by the FDA for patients with chronic kidney disease, with and without T2DM.

Effects of PCSK9i on MACE and death as a function of baseline eGFR in patients with recent ACS

Literature - Sep. 22, 2020 - Tuñón J, et al. - Eur Heart J. 2020

This subanalysis of the ODYSSEY OUTCOME trial evaluated whether the effects of alirocumab, compared to placebo, on MACE and all-cause death are influenced by renal function in patients with recent ACS.

ARNI reduces adverse renal events and slows kidney function decline in HFpEF patients

Literature - Sep. 15, 2020 - Mc Causland FR et al. - Circulation. 2020

This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.

P2Y12i alone reduces bleeding in CKD patients after PCI and 3 months DAPT

News - Sep. 2, 2020

ESC 2020 Ticagrelor monotherapy after 3 months DAPT reduced risk of bleeding without increasing rate of thrombotic events compared to ticagrelor plus aspirin in high risk CDK patients undergoing PCI.

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

SGLT2i reduces risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in CKD

News - Aug. 30, 2020

ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.

Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this e-learning course, participants will learn about diabetic kidney disease and how to manage patients with DKD. Member registration (free) is needed to enroll in this course.

Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This e-learning course focusses on effects of SGLT2 inhibitors on outcomes in CKD patients and (potential) mechanisms of SGLT2 inhibitors. Member registration (free) is needed to enroll in this course.

Primary and all secondary endpoint(s) met for SGLT2i in kidney outcomes trial

News - July 28, 2020

The SGLT2 inhibitor dapagliflozin reduced the primary endpoint and all secondary endpoints in the phase 3 DAPA-CKD trial, that enrolled CKD patients with and without T2DM.

HF development after T2DM diagnosis associated with highest 5-year risk of death

Literature - July 21, 2020 - Zareini B et al., - Circ Cardiovasc Qual Outcomes. 2020.

T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.